Globally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment

Globally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment

Spanning Europe, the United States, and Asia, investors include the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others

Ben Verwaayen appointed as a new Supervisory Board member

Dutch biotech Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced a €40 million investment from the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others. The financing brings together a strong group of impact-focused investors from Europe, the United States, and Asia to support novel approaches that could better protect people worldwide against influenza and other respiratory viruses. Respiratory viruses are a global concern, requiring global access to reach the most vulnerable patients around the world, both in seasonal and pandemic situations.

“This financing represents much more than capital,” said Koenraad Wiedhaup, Founder and CEO of Leyden Labs. “It signals confidence in our scientific approach, our team, and our mission to fundamentally improve how the world protects itself against respiratory viruses. The support from globally respected investors across public health and strategic innovation gives us tremendous momentum as we advance our programs through clinical development and toward global access.”